Home Cart Sign in  
Chemical Structure| 603288-22-8 Chemical Structure| 603288-22-8

Structure of LY2090314
CAS No.: 603288-22-8

Chemical Structure| 603288-22-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2090314 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

Synonyms: LY2090314

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY2090314

CAS No. :603288-22-8
Formula : C28H25FN6O3
M.W : 512.53
SMILES Code : O=C(C(C1=CN2C3=C1C=C(F)C=C3CN(C(N4CCCCC4)=O)CC2)=C5C6=CN=C7C=CC=CN76)NC5=O
Synonyms :
LY2090314
MDL No. :MFCD20526532
InChI Key :HRJWTAWVFDCTGO-UHFFFAOYSA-N
Pubchem ID :10029385

Safety of LY2090314

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of LY2090314

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

Target
  • GSK-3α

    GSK-3α, IC50:1.5 nM

  • GSK-3β

    GSK-3β, IC50:0.9 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV3 and ARK2 cells 10 µM 72 h To assess the cytotoxic effects of LY2090314. PMC5874249

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Metabolic dysfunction-associated steatohepatitis (MASH) Intraperitoneal injection 10 mg/kg 3 times per week for 4 weeks Ameliorated liver inflammation, injury, and fibrosis. PMC11179260
Mice C57BL/6 mouse model Intraperitoneal injection 10 mg/kg twice a week To monitor tumor growth and evaluate the effectiveness of LY2090314 treatment. PMC5874249

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01214603 Leukemia PHASE2 COMPLETED 2025-12-12 For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, 60637, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, 55455, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, 27710, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.20mL

9.76mL

1.95mL

0.98mL

19.51mL

3.90mL

1.95mL

References

 

Historical Records

Categories